Photosonix Medical, Inc.
Photosonix Medical has a proprietary OTC hand-held device to treat the bacterial root cause of acne. No drugs, or pain. It is the future of acne treatment.
- Stage Prototype Ready
- Industry Medical Devices and Equipment
- Location Fort Washington, PA, US
- Currency USD
- Founded April 2014
- Employees 4
- Incorporation Type C-corp
- Website photosonixmed.com
Company Summary
PhotoSonix has developed CLENS, a technology which combines the science of ultrasound and light to treat acne exactly where the problem resides - in the bacterial biofilm below the surface of the skin - providing a highly effective, drug-free way to a beautiful, healthy complexion. CLENS is provided in the form of a hand held device, with companion gels and disposables. CLENS is a new approach to acne and the future of acne treatment.
Team
-
President and COO
Mark Schafer, Ph.D. is an internationally recognized expert in ultrasound technology with 25+ years of medical industry experience. Serial entrepreneur since '84; last 5 years as CTO and VP R&D for Sound Surgical Technologies (Solta), a cosmetic ultrasound surgical company. Tripled product offerings, IP and development pipeline. Prior 10 years as independent consultant. 21 U.S. Patents. BSEE - MIT, MS Acoustics - Penn State, Ph.D. Biomed - Drexel
-
Chief Science Officer
Tessie McNeely, Ph.D. has diverse program and team leadership experience spanning academic, government, and industrial settings. She is a recognized expert on pathogenic bacteria, especially Staphylococcus. Spent 17 years at Merck, Inc. leading teams investigating bacterial infection and immunity, specifically to develop both Staph and acne vaccines; also 4 years at NIH, 2 at Yale. BA - Berea College, PhD Experimental Pathology - UNC Chapel Hill.
-
Executive Chairman
Mark's expertise is in licensing and commercializing skin care technology. His career spans over 30 years in dermatology/cosmeceuticals. He ran the Clearasil brand for Procter & Gamble and the skin care brands for Warner Lambert. For 10 year Mark was the CEO of a privately held business called NeoStrata, with products that were sold in over 80 countries. Mark recently negotiated a highly successful sale of the company to Johnson & Johnson.
Advisors
-
Dr. James LeydenUnconfirmedDr. Guy WebsterUnconfirmedDr. Diane ThiboutotUnconfirmed
Previous Investors
-
Ben Franklin Technology Acceleration FundUnconfirmedPrinceton Biopharma Capital PartnersUnconfirmed
Starting a startup?
Join the world's largest startup network for guidance, tools, and fundraising opportunities.